Flagship Pioneering, LLC Long-Term Concentrated

CIK: 0001400240 · Show all filings

Period: Q2 2019 (← Previous) (Next →)

Filing Date: Aug 13, 2019

Total Value ($000): $2,310,279 (100.0% shares, 0.0% debt)

Holdings (10)

MRNA Moderna Inc 37.3%
Value ($000) $860,940 Shares 58,807,379 Est. Cost $16.43 Unrealized +30.7%
— Rubius Therapeutics Inc 26.1%
Value ($000) $602,404 Shares 38,296,526 Est. Cost $24.00 Unrealized —
KLDO Kaleido Biosciences Inc 8.7%
Value ($000) $201,385 Shares 17,360,710 Est. Cost $13.76 Unrealized +5.8%
DNLI Denali Therapeutics Inc 7.2%
Value ($000) $166,199 Shares 8,005,747 Est. Cost $17.97 Unrealized +24.7%
— Evelo Biosciences Inc 7.1%
Value ($000) $163,736 Shares 18,233,403 Est. Cost $11.80 Unrealized —
— Axcella Health Inc 3.5%
Value ($000) $81,448 Shares 8,748,414 Est. Cost $9.31 Unrealized —
TMDX TransMedics Group Inc 3.2%
Value ($000) $73,352 Shares 2,530,275 Est. Cost $27.30 Unrealized 0.0%
— Seres Therapeutics Inc 3.0%
Value ($000) $69,461 Shares 21,571,764 Est. Cost $8.55 Unrealized —
QTRX Quanterix Corp 2.7%
Value ($000) $61,681 Shares 1,825,412 Est. Cost $19.52 Unrealized +32.5%
— Syros Pharmaceuticals Inc 1.3%
Value ($000) $29,673 Shares 3,204,437 Est. Cost $13.87 Unrealized —